Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?

Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?

Primary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has...

Full description

Bibliographic Details
Main Authors: Erden Atilla, Ugur Sahin, Pinar Ataca Atilla, Mustafa Merter, Elif Ozyurek, Koray Ceyhan, Sinem Civriz Bozdag
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:Hematology/Oncology and Stem Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1658387618300256
id doaj-b41284ce6951485bbc931fb2575f78b9
record_format Article
spelling doaj-b41284ce6951485bbc931fb2575f78b92020-11-25T02:35:18ZengElsevierHematology/Oncology and Stem Cell Therapy1658-38762019-12-01124220225Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?Erden Atilla0Ugur Sahin1Pinar Ataca Atilla2Mustafa Merter3Elif Ozyurek4Koray Ceyhan5Sinem Civriz Bozdag6Ankara University School of Medicine, Department of Hematology, Cebeci, Ankara, Turkey; Corresponding author at: Department of Hematology & BMT, Unit Ankara University Medical School, Cebeci Hospital, 06590 Dikimevi, Ankara, Turkey. Fax: +90 3125957482.Ankara University School of Medicine, Department of Hematology, Cebeci, Ankara, TurkeyAnkara University School of Medicine, Department of Hematology, Cebeci, Ankara, TurkeyAnkara University School of Medicine, Department of Hematology, Cebeci, Ankara, TurkeyAnkara University School of Medicine, Department of Radiology, Cebeci, Ankara, TurkeyAnkara University School of Medicine, Department of Pathology, Sihhiye, Ankara, TurkeyAnkara University School of Medicine, Department of Hematology, Cebeci, Ankara, TurkeyPrimary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whether graft versus lymphoma effect can work in PCNSL patients. Here, we present a relapsed refractory PCNSL case treated by allo-HCT. Keywords: Allogeneic stem cell transplantation, Primary central nervous system lymphoma, Graft versus leukemia effecthttp://www.sciencedirect.com/science/article/pii/S1658387618300256
collection DOAJ
language English
format Article
sources DOAJ
author Erden Atilla
Ugur Sahin
Pinar Ataca Atilla
Mustafa Merter
Elif Ozyurek
Koray Ceyhan
Sinem Civriz Bozdag
spellingShingle Erden Atilla
Ugur Sahin
Pinar Ataca Atilla
Mustafa Merter
Elif Ozyurek
Koray Ceyhan
Sinem Civriz Bozdag
Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?
Hematology/Oncology and Stem Cell Therapy
author_facet Erden Atilla
Ugur Sahin
Pinar Ataca Atilla
Mustafa Merter
Elif Ozyurek
Koray Ceyhan
Sinem Civriz Bozdag
author_sort Erden Atilla
title Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?
title_short Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?
title_full Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?
title_fullStr Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?
title_full_unstemmed Allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: Is it feasible?
title_sort allogeneic stem cell transplantation for relapsed primary central nervous system lymphoma: is it feasible?
publisher Elsevier
series Hematology/Oncology and Stem Cell Therapy
issn 1658-3876
publishDate 2019-12-01
description Primary central nervous system lymphoma (PCNSL), has an aggressive course and in untreated patients median survival is limited to three months. For relapsed PCNSL, the treatment options are few and results are usually unsatisfactory. Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT) has been widely used for treatment of relapsed/refractory NHL patients. However there are limited data whether graft versus lymphoma effect can work in PCNSL patients. Here, we present a relapsed refractory PCNSL case treated by allo-HCT. Keywords: Allogeneic stem cell transplantation, Primary central nervous system lymphoma, Graft versus leukemia effect
url http://www.sciencedirect.com/science/article/pii/S1658387618300256
work_keys_str_mv AT erdenatilla allogeneicstemcelltransplantationforrelapsedprimarycentralnervoussystemlymphomaisitfeasible
AT ugursahin allogeneicstemcelltransplantationforrelapsedprimarycentralnervoussystemlymphomaisitfeasible
AT pinaratacaatilla allogeneicstemcelltransplantationforrelapsedprimarycentralnervoussystemlymphomaisitfeasible
AT mustafamerter allogeneicstemcelltransplantationforrelapsedprimarycentralnervoussystemlymphomaisitfeasible
AT elifozyurek allogeneicstemcelltransplantationforrelapsedprimarycentralnervoussystemlymphomaisitfeasible
AT korayceyhan allogeneicstemcelltransplantationforrelapsedprimarycentralnervoussystemlymphomaisitfeasible
AT sinemcivrizbozdag allogeneicstemcelltransplantationforrelapsedprimarycentralnervoussystemlymphomaisitfeasible
_version_ 1724804230637682688

Similar Items